INTRODUCTION
Polycystic ovarian syndrome (PCOS) was first described by Valisneri in 1721[1] as, “Young, married peasant women, moderately obese, and infertile with two larger than normal ovaries, bumpy, shiny and whitish, just like pigeon eggs”. In 1935, Stein and Leventhal published a case series of seven women with amenorrhea, hirsuitism, obesity, and ovaries with a grossly polycystic appearance.[2] The syndrome is one of the commonest endocrinopathies in women of reproductive age causing significant menstrual and fertility issues and over the past few decades its metabolic, cardiovascular, and reproductive risks have become apparent.[3] In spite of tremendous scientific interest and research, controversy continues regarding...
almost all aspects of PCOS. Diagnosis, prevalence, etiology, pathophysiology, management, long-term risks, etc. Also, clinical and biochemical features of these women may vary according to race, ethnicity, and criteria used for diagnosis.\[14\] Diagnosis of PCOS continues to be controversial primarily because of the heterogenous nature of the condition which may change during the lifetime of the woman. Currently, the commonest criteria used for diagnosis of PCOS is the “Rotterdam criteria” which includes any two of the following three features:

1) Oligo/anovulation (O), 2) clinical and/or biochemical hyperandrogenemia (H), 3) polycystic ovaries on ultrasound (P), with exclusion of other known disorders of hyperandrogenemia. This generates four different phenotypes: 1) P + H + O (PCOS complete), 2) P + O, 3) H + O, and 4) P + H (5). Diagnosis of PCOS is important, because it is associated with increased risks of insulin resistance (IR), noninsulin dependent diabetes mellitus and metabolic syndrome. All of which have long-term consequences.\[15-16\] PCOS women have a 11-fold higher risk of having metabolic syndrome, which is a cluster of endocrine disturbances like IR, dyslipidemia, obesity, hypertension, atherosclerosis, and endothelial dysfunction\[16-18\] compared to age matched controls.\[11\] The original National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria in 2001 defines metabolic syndrome as the co-occurrence of three or more of the following risk factors: 1) Waist circumference (WC) ≥ 88 cm in women, 2) blood pressure ≥130/85 mmHg, 3) fasting serum glucose ≥110 mg/dl, 4) fasting serum triglyceride ≥150 mg/dl, and 5) fasting high density lipoprotein <50 mg/dl.\[12\] Currently, modified American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) definition (ATP III 2005) includes the following changes: 1) Defining the ethnic specific difference in central obesity by using the World Health Organization (WHO) recommendation for WC as ≥80 cm in Asian women and 2) reduced threshold for impaired fasting glucose to 100 mg/dl in accordance with American Diabetes Association revised definition.\[13\]

Hyperinsulinemia and IR are thought to be key pathological factors for PCOS and metabolic syndrome.\[14,15\] IR is a metabolic disorder characterized by impairment of insulin function. Diagnosis of IR is not standardized.\[16\] Many techniques are followed, for example: Fasting plasma glucose, 2 h 75 g oral glucose tolerance test (OGTT), glucose/insulin ratio, homeostasis model assessment for IR (HOMA-IR), quantitative insulin sensitivity check index (Quiki) and euglycemic hyperinsulinemic clamp which is considered the gold standard.\[17,18\] Superiority of one over the other is not established. In the present study, HOMA-IR was used to diagnose IR. Prevalence of acanthosis nigricans was also reported. Acanthosis nigricans is a brown to black poorly defined; velvety hyperpigmentation of the skin; usually present in the posterior and lateral folds of neck, axilla, and groin. This clinical finding correlates well with IR.\[19\]

The prevalence of metabolic syndrome and IR in PCOS has been studied in very few different populations and ethnic groups. Also, there are limited data on differences between various phenotypes with respect to long-term metabolic risk. Especially the newer phenotypes generated by the Rotterdam criteria are inadequately studied and reported. This study was undertaken to characterize the various phenotypes of PCOS. Their distribution, clinical, anthropometric, and biochemical features and to report the prevalence and risk factors for metabolic syndrome and IR in the different phenotypes on our population.

**MATERIALS AND METHODS**

This prospective cross-sectional comparative study was conducted from January 2009 to December 2012, in a private hospital with a large gynecologic practice. All women in the reproductive age group (18-45) with the primary complains of menstrual irregularities with or without infertility were evaluated in detail for PCOS. All those with a final diagnosis of PCOS were included in the study. PCOS was diagnosed according to the 2003 Rotterdam criteria (European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) PCOS consensus workshop group) with at least two of the following three features; (i) oligo anovulation (ii) clinical and/or biochemical hyperandrogenism, and (iii) ultrasound appearance of polycystic ovaries. Four hundred and ten women with PCOS qualified for the study.

All participants gave written informed consent and this study was approved by our ethics committee.

All anthropometric measurements were done following standard protocol and calibrated instruments by a single technician. All clinical findings like F-G score, acanthosis nigricans, galactorrhea, etc., were evaluated by single gynecologist. All sonographies were performed by single gynecologist (author) (voluson E8). All biochemical and hormonal tests were carried out in the laboratory of the private hospital where this study was conducted (miniVidas, bioMerieux), except serum sex hormone binding globulin (SHBG) and free testosterone, which were outsourced to a standard national laboratory (Thyrocare Technologies Limited). Evaluation of reports and final diagnosis of PCOS was made by single gynecologist (author).

Oligo and anovulation was defined as: Menstrual cycles <21 days or >35 days, clinical hyperandrogenism was
defined as modified Ferriman Gallway score ≥8. Biochemical hyperandrogenism as a free androgen index (FAI) of >4.5 (total testosterone, nmol/l/SHBG, nmol/l × 100). Polycystic ovary was defined as ≥12 follicles per ovary and/or ovarian volume ≥10 cm³. All participants gave fasting (>12 h) blood samples for plasma glucose, insulin, lipid profile, follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, thyroid stimulating hormone (TSH), total testosterone, and SHBG. Sonography was performed in early follicular phase. Metabolic syndrome was defined according to the modified AHA/NHLBI ATP III (2005) definition. It was diagnosed if at least three of the following five features were present: 1) WC of ≥ 80 cm, 2) blood pressure of ≥130/85 mmHg, 3) fasting blood sugar of ≥100 mg/dl, 4) triglycerides of ≥150 mg/dl, and 5) high density lipoprotein (HDL) of ≤50 mg/dl.

IR was estimated using the HOMA-IR (fasting insulin μU/ml × fasting glucose (mg/dl)/405). IR was present with a HOMA-IR value of ≥3.8.

**Statistical analysis**
Quantitative variables were expressed as mean ± standard deviation (SD) and were compared between groups using one way analysis of variance (ANOVA), ANOVA, and “Tamhane” post hoc statistical tests. Quantitative variables were expressed as frequencies in percentages and were analyzed by χ² tests. Multivariate logistic regression analysis was used to examine independent predictors of metabolic syndrome. Statistical analysis was done using SPSS version 18. A P value of less than 0.05 was considered statistically significant.

**RESULTS**
The largest phenotypic group was women with all three features, that is, PCO complete P + O + H (65.6%). Followed by P + O (22.2%), the normoandrogenic phenotype; and then H + O (11.2%), the non-PCO phenotype. The ovulatory phenotype, H + P was the least common (0.9%). The mean and SD of clinical and demographical characteristics of these four phenotypes are presented in Table 1. The hyperandrogenic phenotype, that is, P + O + H, H + O, as defined by National Institute of Child Health and Human Development (NICHD, 1990) comprised 76.8%. The newer phenotypes which were added after the Rotterdam criteria (2003), that is, P + O and P + H comprised 23.1%.

The overall prevalence of metabolic syndrome was 35.07%. In the hyperandrogenic anovulatory phenotype H + O metabolic syndrome was present in 50% of women. In PCO complete P + H + O 37.4% and in P + O phenotype the prevalence of metabolic syndrome was low, that is, 10%.

Clinical and biochemical parameters of PCOS women with and without metabolic syndrome was compared [Table 2]. There was statistically significant difference between the two groups in age (P = 0.013), BMI (P < 0.0004), WC (P < 0.0003), waist-hip ratio (W/H) (P = 0.014), serum fasting insulin (P = 0.0004), total cholesterol (P = 0.004), triglycerides (P = 0.03), and systolic and diastolic blood pressure (P < 0.00003 and 0.0005, respectively).

The prevalence of metabolic syndrome increased with age [Figure 1] and with increasing BMI [Figure 2]. The age adjusted prevalence of metabolic syndrome in different phenotypes is shown in Figure 3.

In obese women (BMI ≥30), prevalence of metabolic syndrome was 41%, against 13.3% in lean women (BMI ≤ 24.9). Overall 62.5% of PCOS women were overweight, 73.9% had WC above the cutoff of ≥80 cm. Acanthosis nigricans was detected in 37.5% of all PCOS women. In women with metabolic syndrome and IR, approximately 65% women showed this classic sign.

Logistic regression analysis showed that BMI (OR = 3.07 (1.65-5.71 95% CI)); WC ≥ 80 cm (OR = 3.68 (1.68-8.07 95% CI)); P + O (OR = 0.0004), waist-hip ratio (W/H) (P = 0.014), acanthosis nigricans (OR 3.53 (2.10-5.92 95% CI); P < 0.0001) and family history of diabetes were independent predictors of metabolic syndrome.

**Table 1: Anthropometric and clinical data of different polycystic ovary syndrome phenotypes**

|                      | Group I P+H+O N=269 (65.6%) | Group II P+O N=91 (22.2%) | Group III H+O N=46 (11.2%) | Group IV P+H N=4 (0.9%) | P value |
|----------------------|-----------------------------|---------------------------|---------------------------|-------------------------|---------|
| Age                  | 24.08±4.12                  | 24.41±3.64                | 24.93±3.97                | 26.5±6.24               | 0.3349  |
| Weight               | 64.36±10.83                 | 60.31±12.6                | 65.16±11.94               | 61±13.51                | 0.0199  |
| BMI                  | 26.9±5.59                   | 26.95±5.6                 | 31.47±3.3                 | 24.93±4.12              | 0.0949  |
| WC                   | 87.38±10.89                 | 82.3±14.5                 | 85.77±15.35               | 89.25±17.69             | 0.0101  |
| HC                   | 96.87±12.52                 | 94.88±13.57               | 97.88±10.38               | 98.75±10.34             | 0.0488  |
| Fasting insulin      | 95.25±12.54                 | 90.18±8.39                | 94.55±15.8                | 92±13                   | 0.0908  |
| Fasting insulin      | 14.14±9.88                  | 10.32±7.48                | 16.85±14.05               | 2.52                    | 0.0547  |
| HOMA-IR              | 3.43±2.71                   | 2.9±2.2                   | 4.19±3.05                 | 0.5                     | 0.1726  |
| HDL-C                | 40.5±9.61                   | 39.47±5.2                 | 39.32±4.35                | 40.1                    | 0.8927  |

BMI=Body mass index; WC=Waist circumference; FBS=Fasting blood glucose; HOMA-IR=Homeostatic model assessment-insulin resistance; HDL-C=High density lipoprotein-cholesterol; O=Oligoanovulation; H=Clinical and/or biochemical hyperandrogenemia; P=Polycystic ovaries on ultrasound.
(OR = 1.82 (1.10-3.01 95% CI); P = 0.02), were associated with the risk of having metabolic syndrome [Table 3].

IR (HOMA-IR ≥ 3.8) was present in 30.44% of all PCOS women. Since there is no consensus on cutoff levels of HOMA-IR to define presence of IR, multiple cutoffs of HOMA-IR were used. With a HOMA-IR cutoff of ≥3.5 and ≥2.5, IR was present in 34.95 and 50.52% of PCOS women, respectively. Prevalence of IR varied in different phenotypes. It was highest in hyperandrogenic anovulatory phenotype H + O (35.13%) followed by P + H + O (31.58%) and P + O (21.05%).

**DISCUSSION**

The phenotypic distribution in our study in order of decreasing prevalence was: P + O + H; P + O; O + H; and P + H (65.6, 22.2, 11.2, and 0.9%, respectively). In few similar studies the phenotypic distribution was quite similar. Turkish population 44.09, 14.17, 18.9, and 14.1%; Bulgarian 53.6, 11, 12.8, and 22.6%; United States 58, 13, 14, and 14%; and Iranian 32.1, 46.8, 14.8, and 6.3%, respectively.[20‑23] PCO complete (P + O + H) was the largest group in most reports. Normoandrogenic phenotype (P + O) comprised a significant proportion of PCOS women. Ovulatory phenotype P + H, was the least common group, possibly because these woman are mostly asymptomatic and unlikely to present in gynecology outpatient. Also, women

![Figure 1: Distribution of metabolic syndrome by age](image1)

![Figure 2: Distribution of metabolic syndrome by body mass index](image2)

![Figure 3: Age adjusted prevalence of metabolic syndrome in different polycystic ovary syndrome phenotypes](image3)
with hyperandrogenic symptoms like acne and hirsutism are more likely to consult dermatology.

The overall prevalence of metabolic syndrome in our population of PCOS women was 35.07%. Similar studies from different populations have reported prevalence of metabolic syndrome. American 43-46%,[11] Italian 8.2%,[24] Iranian 24.9%,[23] German 33.8%,[30] and Indian 46.2 and 37.5%.[27] The differences in the above studies may be as a result of different body weights, dietary habits, lifestyle, and genetic factors in different countries and ethnic groups. Also different criteria for diagnosis of metabolic syndrome like NCEP ATP III and International Diabetic Federation (IDF) criteria. A recent consensus definition incorporating IDF and AHA/NHLB risk factors have been introduced.[28] Our study has used this definition for the definition of metabolic syndrome. Thus, our findings are comparable with the other Indian study[27] reporting 37.5% prevalence of metabolic syndrome in PCOS women with infertility.

Our study also aimed to characterize and compare the prevalence of metabolic complications of the four PCOS phenotypes. The hyperandrogenic phenotypes had a four- to five-fold higher (37-50%) prevalence of metabolic syndrome compared to the non-hyperandrogenic phenotype (10%). Suggesting that P + O created by the Rotterdam criteria, one of the new phenotypes, have a mild metabolic profile. Many studies have reported similarly.[22,23,29,30]

IR, hyperinsulinemia, and hyperandrogenemia are likely pathogenic factors in PCOS.[31-33] Polycystic morphology on ultrasound, its mechanism and importance is not understood. Studies however report lower incidence of metabolic syndrome, IR, lower cholesterol, and low density lipoproteins in women with PCO ovary.[22,23,29,30,34]

In our study obese women (BMI ≥ 30) had three- to four-fold higher prevalence of metabolic syndrome compared to lean women (BMI ≤ 24.9), 41 vs 13.3%, which is similar to other studies.[23,25,27] Surprisingly, Shroff et al.,[22] reported not a single case of metabolic syndrome PCOS women with BMI < 30. In our lean PCOS women with metabolic syndrome the major components were; abnormal WC and low HDL cholesterol. Thus, significant number of lean women had abnormal WC and W/H ratio.

IR was reported based on HOMA-IR values, which could be one of the limitations of this study. Diagnosis of IR is not standardized.[35] The gold standard for establishing IR is euglycemic hyperinsulinemic clamp and is often used as a surrogate marker. However, the cutoff or threshold values for HOMA-IR are not established. Using a cutoff of 3.8 may underestimate the true prevalence of IR.[16-18] Approximately, 50-70% of all women with PCOS have some degree of IR.[36] True prevalence is difficult to determine with no universally accepted parameter to measure IR. As reported by us using different cutoff for HOMA-IR, the prevalence may range from 30 to 50%.

Currently there is lack of consensus on how best to evaluate insulin sensitivity. Homeostasis measurements (fasting glucose/insulin ratio or HOMA-IR values) and minimal model tests (OGTT) represent the easiest screening methods.[36] Possibly OGTT is the best, simple test to provide information about both IR and glucose intolerance. Diagnosis of glucose intolerance gives greater scope for treatment options and prognosis. So, from clinical prognosis and management point of view doing 75 g 2 h OGTT is the most informative. HOMA-IR is not of much practical importance.

Multivariate logistic regression analysis showed that age ≥25 years, WC ≥ 80 cm, and BMI and family history of diabetes were strong risk factors for metabolic syndrome. These correlate well with other studies which concluded that WC is closely related with obesity related risk factors as compared with BMI.[27,37]

The major limitations of our study is the absence of control group which should be age and BMI matched to the PCOS group. Nonavailability of educated and informed volunteers to participate in such studies is the main hurdle.

CONCLUSION

An appropriate diagnosis of PCOS and accurate identification of phenotype is very important as it has long-term health implications for women. These women need to be informed and counseled about their present and long-term risks. Our study is the first to characterize phenotypes of PCOS in a large cohort of women and to show the data of various metabolic complications of these phenotypes. Our findings highlights that normoandrogenic phenotype has least metabolic risks. Also, significant proportion of lean PCOS women have abnormal WC, W/H ratio, and metabolic abnormalities. Therefore, we recommend screening all PCOS women for metabolic abnormalities.

ACKNOWLEDGEMENT

I would like to acknowledge that this work has been possible only with the support of the entire staff of Obstetrics and
REFERENCES

1. Insler V, Lunenfeld B. Polycystic ovarian disease: A challenge and controversy. Gynecol Endocrinol 1990;4:51-70.
2. Stein KE, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
4. Kauffman RP, Baker VM, Dimarino P, Gimpel T, Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: A comparison of two distinct populations. Am J Obstet Gynecol 2002;187:1362-9.
5. Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
6. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-Cholesterol ratio in nondiabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003;10:186-91.
7. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein Lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-51.
8. Gugick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am J Obstet Gynecol 1996;174:1224-9.
9. Birdsall MA, Farquhar CM, White HD. Association between Polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-5.
10. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-5.
11. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131-7.
12. Lepor NE, Vogel RE. National Cholesterol Education Program Adult Treatment Panel III. Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III. Rev Cardiovas Med 2001;2:160-5.
13. Grundy SM, Cleeman JL, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
14. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and Intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-66.
15. Haffner SM, D’Agostino JR Jr, Festa A, Bergman RN, Mykkanen L, Karter A, et al. Low insulin sensitivity (S (i)=0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: Is it associated with components of the metabolic syndrome and non-traditional risk factors? Diabetes Care 2003;26:2796-803.
16. Lebovitz HE. Insulin resistance: Definition and consequences. Exp Clin Endocrinol Diabetes 2001;109 Suppl 2:S135-48.
17. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
18. Mather K. Surrogate measures of insulin resistance: Of rats, mice and men. Am J Physiol Endocrinol Metab 2009;296:E398-9.
19. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes 1985;34:101-7.
20. Yilmaz M, Isagolu U, Delibas IB, Kadanali S. Anthropometric, clinical and laboratory comparison for our phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res 2011;37:1020-6.
21. Kavazdihkova S, Pechivanov B. Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population. Akush Ginekol (Sofia) 2010;49:32-7.
22. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. RRisk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007;88:1389-95.
23. Mehrabian F, Khasi B, Kelifshadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 2011;16:763-9.
24. Carmina E, Napoli N, Longo RA, Kini GR, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): Lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006;154:141-5.
25. Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K, et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2007;115:130-5.
26. Bhattacharya SM. Metabolic Syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res 2008;34:62-6.
27. Mandrell K, Kamath MS, Bondu DJ, Chandy A, Aleyamma TK, George K. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. J Hum Reprod Sci 2012;5:26-31.
28. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JL, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
29. Apridonidze T, Essah PA, Ioorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-35.
30. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-15.
31. Ciardiello F, Grimaldi A, De Lucia A, Cappellini G, Spadoni S, Bilotta M, et al. Cellular mechanisms of insulin resistance in Polycystic ovarian syndrome. J Clin Endocrinol Metab 1992;75:577-83.
32. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrinol Rev 1997;18:774-800.
33. De Ziegler D, Rosenfield RL. Insulin-like growth factor I and Insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988;123:733-9.
34. Kauffman RP, Baker TE, Baker VM, DiMarco P, Castracane VD. Endocrine and metabolic difference among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670.e1-7.
35. Lufer B, Wildt S, Seebacher A. Accurate screening for insulin resistance in...
Kar: Phenotypic characterizations of the Indian PCOS women

PCOS women using fasting insulin concentrations. Gynecol Endocrinol 2013;29:541-4.

36. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-54.

37. Janssen I, Katzmarzyk PT, Ross P. Waist circumference and not body mass index explains obesity related health risks. Am J Clin Nutr 2004;79:379-84.

How to cite this article: Kar S. Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: A prospective study of PCOS women. J Hum Reprod Sci 2013;6:194-200.

Source of Support: Nil, Conflict of Interest: None declared.

New features on the journal’s website

Optimized content for mobile and hand-held devices
HTML pages have been optimized of mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed.
Click on [Mobile Full text] from Table of Contents page.
This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version)

E-Pub for hand-held devices
EPUB is an open e-book standard recommended by The International Digital Publishing Forum which is designed for reflowable content i.e. the text display can be optimized for a particular display device.
Click on [EPub] from Table of Contents page.
There are various e-Pub readers such as for Windows: Digital Editions, OS X: Calibre/Bookworm, iPhone/iPod Touch/iPad: Stanza, and Linux: Calibre/Bookworm.

E-Book for desktop
One can also see the entire issue as printed here in a ‘flip book’ version on desktops.
Links are available from Current Issue as well as Archives pages.
Click on View as eBook